Business Context and Reporting Period
Company: NanoViricides, Inc. (NNVC)
Filing Type: Form 8-K (Current Report)
Reporting Date: November 10, 2025 (Event Date)
Closing Date: November 12, 2025
Context: The Company entered into a Securities Purchase Agreement with an institutional investor to conduct a Registered Direct Offering and a concurrent private placement (PIPE Offering).
Key Financial Metrics and Transaction Details
Aggregate Gross Proceeds: Approximately $6.0 million (before fees and expenses).
Use of Proceeds: Working capital and general corporate purposes.
Placement Agent Fees: 7.0% of aggregate gross proceeds, plus reimbursement of up to $60,000 in fees/expenses and $15,000 in non-accountable expenses.
| Security Type | Quantity | Price per Unit | Exercise Price (if applicable) |
|---|---|---|---|
| Common Stock | 1,970,000 shares | $1.68 | N/A |
| Pre-Funded Warrants | 1,601,429 warrants | $1.67999 | $0.00001 |
| Series A Warrants | 3,571,429 warrants | Issued in PIPE | $1.75 |
| Series B Warrants | 3,571,429 warrants | Issued in PIPE | $2.00 |
Note: The filing does not provide specific revenue, profit, cash flow, margin, or debt figures for the reporting period.
Material Changes and Transaction Structure
- Capital Raise: The Company raised approximately $6.0 million through a combination of common stock, pre-funded warrants, and standard warrants.
- Warrant Terms:
- Pre-Funded Warrants: Immediately exercisable at $0.00001.
- Series A Warrants: Exercisable after 6 months; expire in 2 years.
- Series B Warrants: Exercisable after 6 months; expire in 5.5 years.
- Lock-Up Agreements: Directors and executive officers are restricted from selling or transferring shares for 90 days following the Closing Date.
- Issuance Restrictions: The Company agreed not to issue additional common stock or equivalents for 90 days and not to enter into Variable Rate Transactions for 180 days post-closing.
Outlook, Risks, and Management Commentary
Management Commentary: The Company intends to utilize the net proceeds for working capital and general corporate purposes. The offering was executed pursuant to an effective shelf registration statement (Form S-3) filed in May 2023.
Risks and Contingencies:
- Dilution: The issuance of common stock and warrants will result in dilution to existing shareholders.
- Market Volatility: The exercise prices of the Series A and Series B warrants ($1.75 and $2.00) are set above the offering price of the common stock ($1.68), creating a hurdle for immediate exercise profitability.
- Liquidity Constraints: The 90-day lock-up for insiders and the 90-day issuance blackout period may impact short-term liquidity and capital flexibility.
Key Facts for Investor Verification
- Verify the exact net proceeds after deducting the 7% placement fee and estimated expenses.
- Confirm the total number of shares outstanding post-closing to assess immediate dilution impact.
- Review the specific terms of the "Variable Rate Transaction" restriction to understand future financing limitations.
- Monitor the Company's cash burn rate to determine how long the $6.0 million in gross proceeds will sustain operations.
- Check for any subsequent filings regarding the exercise of Pre-Funded Warrants, which are immediately exercisable.